Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 AUG 17 ... Pain Medication, Pharmaceutical Business, Pharmaceutical Company, Pharmaceuticals, Rofecoxib, Therapy, Treatment, Vioxx. This article was prepared by Pain & Central ...
2009 NOV 23 ... Pharmaceuticals, Drugs, Therapy, Treatment, Olanzapine, Zyprexa, Drospirenone, Yasmin, Rofecoxib, Vioxx This article was prepared by Biotech Business Week editors from ...
Subject: Burg Simpson Eldredge Hersh & Jardine, P.C.
2009 AUG 31 ... hip replacement. were randomized to receive enteric-coated diclofenac 50 mg (n = 18), rofecoxib 12.5 mg (n = 17) or placebo (n = 16) administered orally three times daily for 2 weeks ...
2009 AUG 17 ... but not antinociceptive activity, whereas clonidine exhibited both activities and rofecoxib, used as negative control, showed neither," wrote J.M. Entrena and colleagues, ...
2009 JUL 27 ... to receive naproxcinod 750 mg once daily (qd), 750 mg twice daily (bid), 1125 mg bid, rofecoxib 25 mg qd, or placebo for 6 weeks," investigators in the United States report. ...
2009 JUL 6 ... a drug, such as the occurrence of a cardiovascular event while the patient is taking rofecoxib. As this type of ADR is often mistaken for a spontaneous disease, the causative agent ...
2009 JUL 21 ... Protection, Homeowners, Insurance, Manufacturing, Real EstateDrugs, Pharmaceuticals, Rofecoxib, Therapy, Treatment, Vioxx. This article was prepared by Drug Law Weekly ...
2009 NOV 2 ... Celebrex, Celecoxib, Drug Development, Drugs, FDA, Pain Medicine, Pharmaceuticals, Rofecoxib, Therapy, Treatment, U.S. Food and Drug Administration, Valdecoxib, Vioxx, University of ...
2009 OCT 19 ... renal, and cardiac effects of 4-(4-methylsulfonylphenyl)-3-phenyl-5H-furan-2-one (rofecoxib; a COX2 inhibitor) and 6-{5-[(cyclopropylamino) ...
2009 AUG 10 ... expression (R=-0.68, R2=0.46, p=0.03). Administration of the selective COX-2 inhibitor rofecoxib to patients with CRC (n=5) induced DRAK2 expression in tumours (2.5-fold increase, ...
2009 NOV 1 ... undergoing elective, outpatient, unilateral inguinal herniorrhaphy. Patients received rofecoxib (50 mg, 1 h prior to incision) or placebo. Doses were re-administered once daily on ...
2009 NOV 9 ... with tumor stage. NR4A2 levels were reduced in adenomas From patients treated with rofecoxib. Down-regulation of osteopontin, probably through blockade of NR4A2 and Writ signaling, ...
2009 AUG 24 ... in growth medium." "This bacterial killing, however, was not noted with rofecoxib, despite its higher potency than that of celecoxib in inhibiting cyclooxygenase-2. The ...
2009 AUG 31 ... and Drug Administration's Adverse Event Reporting System (AERS) involving the use of rofecoxib. and methods: The authors studied all adverse events involving...
2009 AUG 17 ... therapy. Administration of curcumin (240 mg/kg i.p.), aspirin (160 mg/kg i.p.) at rofecoxib (5 mg/kg i.p.) for 6 days in the cotton pellet granuloma pouch test exhibited ...
2009 NOV 16 ... higher levels as compared to other coxibs (etoricoxib, valdecoxib, lumiracoxib, and rofecoxib) in different tumor cell types, including human HCA-7 and HCT-116 colon carcinoma cells, ...
